Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $39.00.

A number of research analysts have recently commented on ARTV shares. Wedbush increased their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. HC Wainwright increased their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $7.27 on Wednesday. The firm has a market capitalization of $179.71 million, a P/E ratio of -2.05 and a beta of 2.38. The business’s 50-day moving average is $8.82 and its two-hundred day moving average is $6.05. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, analysts expect that Artiva Biotherapeutics will post -2.45 EPS for the current year.

Insiders Place Their Bets

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. acquired 6,510,416 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $11.52 per share, for a total transaction of $74,999,992.32. Following the acquisition, the director owned 15,203,995 shares in the company, valued at $175,150,022.40. The trade was a 74.89% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Subhashis Banerjee sold 7,037 shares of the stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $63,403.37. Following the completion of the transaction, the insider owned 144,963 shares in the company, valued at approximately $1,306,116.63. The trade was a 4.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have bought 7,942,707 shares of company stock worth $91,499,985 and have sold 53,040 shares worth $477,890. Insiders own 21.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC grew its stake in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares during the last quarter. Marshall Wace LLP purchased a new position in Artiva Biotherapeutics during the 4th quarter worth approximately $341,000. Jane Street Group LLC purchased a new position in Artiva Biotherapeutics during the 2nd quarter worth approximately $67,000. Finally, Landscape Capital Management L.L.C. purchased a new position in Artiva Biotherapeutics during the 3rd quarter worth approximately $112,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.